Barclays
GLSI icon

Barclays’s Greenwich LifeSciences GLSI Stock Holding History

Barclays’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9K Sell
850
-309
-27% -$7.52K ﹤0.01% 4584
2026
Q1 		$27.8K Sell
1,159
-8,585
-88% -$224K ﹤0.01% 4501
2025
Q4 		$205K Buy
9,744
+1,030
+12% +$10.8K ﹤0.01% 4295
2025
Q3 		$86.7K Sell
8,714
-1,868
-18% -$21.1K ﹤0.01% 4650
2025
Q2 		$96K Buy
10,582
+3,949
+60% +$37.6K ﹤0.01% 4585
2025
Q1 		$63.3K Sell
6,633
-3,015
-31% -$36.6K ﹤0.01% 4557
2024
Q4 		$108K Buy
9,648
+1,088
+13% +$14.6K ﹤0.01% 4576
2024
Q3 		$123K Buy
8,560
+6,538
+323% +$96.9K ﹤0.01% 4516
2024
Q2 		$34.9K Buy
+2,022
New +$29.5K ﹤0.01% 4329
2022
Q2 		– Sell
-665
Closed -$13K – 5117
2022
Q1 		$13K Buy
+665
New +$13.4K ﹤0.01% 4549

Other funds holding GLSI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's GLSI Position: Q2 2026 in Review

Barclays reduced its Greenwich LifeSciences (GLSI) stake by 27% in Q2 2026, selling an estimated $7.52K and leaving 850 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4584.

Barclays first reported a position in GLSI in Q1 2022 and has held it in 10 quarters since. The position peaked at $205K in Q4 2025. 57 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • Barclays held 850 shares of Greenwich LifeSciences worth $19.9K as of Q2 2026.
  • Barclays sold 309 Greenwich LifeSciences shares in Q2 2026, an estimated $7.52K.
  • Greenwich LifeSciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4584 holding.
  • Barclays first reported a position in Greenwich LifeSciences in Q1 2022 and has held it in 10 quarters since.
  • Barclays's Greenwich LifeSciences position peaked at $205K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.